BR112014014181A2 - combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer - Google Patents
combinação de ozogamicina inotuzumab e torisel para o tratamento de câncerInfo
- Publication number
- BR112014014181A2 BR112014014181A2 BR112014014181A BR112014014181A BR112014014181A2 BR 112014014181 A2 BR112014014181 A2 BR 112014014181A2 BR 112014014181 A BR112014014181 A BR 112014014181A BR 112014014181 A BR112014014181 A BR 112014014181A BR 112014014181 A2 BR112014014181 A2 BR 112014014181A2
- Authority
- BR
- Brazil
- Prior art keywords
- ozogamycin
- inotuzumab
- combination
- temsirolimus
- torisel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576831P | 2011-12-16 | 2011-12-16 | |
| PCT/IB2012/056958 WO2013088304A1 (en) | 2011-12-16 | 2012-12-04 | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014014181A2 true BR112014014181A2 (pt) | 2017-06-13 |
Family
ID=47557418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014181A BR112014014181A2 (pt) | 2011-12-16 | 2012-12-04 | combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9642918B2 (https=) |
| EP (1) | EP2790723A1 (https=) |
| JP (1) | JP2013126979A (https=) |
| KR (2) | KR20170049617A (https=) |
| CN (1) | CN104023747A (https=) |
| AU (2) | AU2012351728A1 (https=) |
| BR (1) | BR112014014181A2 (https=) |
| CA (1) | CA2859089A1 (https=) |
| HK (1) | HK1201191A1 (https=) |
| IL (1) | IL233165A0 (https=) |
| MX (1) | MX2014007077A (https=) |
| RU (1) | RU2607594C2 (https=) |
| WO (1) | WO2013088304A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016540826A (ja) | 2013-11-04 | 2016-12-28 | ファイザー・インク | 抗ｅｆｎａ４抗体−薬物コンジュゲート |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| WO2016201481A1 (en) * | 2015-06-15 | 2016-12-22 | Newsouth Innovations Pty Limited | Pharmaceutical combinations of organo-arsenoxide compounds and mtor inhibitors |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| CN110998319A (zh) * | 2017-06-06 | 2020-04-10 | 约翰霍普金斯大学 | 用表观遗传疗法诱导合成致死性 |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| AU2020221271A1 (en) * | 2019-02-13 | 2021-10-07 | Coimmune, Inc. | Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| MX2022004326A (es) * | 2019-10-10 | 2022-07-27 | Bryologyx Inc | Método para la inducción de antígenos asociados al tumor con briostatina. |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US4667637A (en) | 1986-01-08 | 1987-05-26 | Brunswick Corporation | Gated knock detector for internal-combustion engines |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| DK0525960T3 (da) | 1991-06-18 | 1996-04-15 | American Home Prod | Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| WO2007125252A1 (fr) | 2006-04-26 | 2007-11-08 | France Telecom | Procede et systeme de gestion d'un paiement electronique |
| GB0609378D0 (en) * | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
| WO2010057047A1 (en) * | 2008-11-13 | 2010-05-20 | Trubion Pharmaceutics, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
| US7998973B2 (en) * | 2009-11-13 | 2011-08-16 | Aveo Pharmaceuticals, Inc. | Tivozanib and temsirolimus in combination |
| BR112012013093A2 (pt) * | 2009-12-21 | 2017-12-12 | Genentech Inc | ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável |
| RU2585489C2 (ru) * | 2010-04-27 | 2016-05-27 | Рош Гликарт Аг | КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR |
-
2012
- 2012-12-04 AU AU2012351728A patent/AU2012351728A1/en not_active Abandoned
- 2012-12-04 WO PCT/IB2012/056958 patent/WO2013088304A1/en not_active Ceased
- 2012-12-04 HK HK15101740.4A patent/HK1201191A1/xx unknown
- 2012-12-04 CN CN201280062130.7A patent/CN104023747A/zh active Pending
- 2012-12-04 KR KR1020177011120A patent/KR20170049617A/ko not_active Ceased
- 2012-12-04 BR BR112014014181A patent/BR112014014181A2/pt not_active IP Right Cessation
- 2012-12-04 KR KR1020147018997A patent/KR20140107413A/ko not_active Ceased
- 2012-12-04 EP EP12813985.4A patent/EP2790723A1/en not_active Ceased
- 2012-12-04 US US14/365,793 patent/US9642918B2/en not_active Expired - Fee Related
- 2012-12-04 MX MX2014007077A patent/MX2014007077A/es unknown
- 2012-12-04 CA CA2859089A patent/CA2859089A1/en not_active Abandoned
- 2012-12-04 RU RU2014124005A patent/RU2607594C2/ru not_active IP Right Cessation
- 2012-12-14 JP JP2012273427A patent/JP2013126979A/ja active Pending
-
2014
- 2014-06-16 IL IL233165A patent/IL233165A0/en unknown
-
2016
- 2016-04-26 AU AU2016202621A patent/AU2016202621B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| HK1201191A1 (en) | 2015-08-28 |
| KR20170049617A (ko) | 2017-05-10 |
| CA2859089A1 (en) | 2013-06-20 |
| CN104023747A (zh) | 2014-09-03 |
| IL233165A0 (en) | 2014-07-31 |
| JP2013126979A (ja) | 2013-06-27 |
| MX2014007077A (es) | 2015-03-06 |
| WO2013088304A1 (en) | 2013-06-20 |
| EP2790723A1 (en) | 2014-10-22 |
| AU2012351728A1 (en) | 2014-06-19 |
| AU2016202621B2 (en) | 2017-11-02 |
| RU2607594C2 (ru) | 2017-01-10 |
| RU2014124005A (ru) | 2016-02-10 |
| KR20140107413A (ko) | 2014-09-04 |
| US20140335109A1 (en) | 2014-11-13 |
| AU2016202621A1 (en) | 2016-05-26 |
| US9642918B2 (en) | 2017-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014181A2 (pt) | combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| BR112013007681A2 (pt) | uso terapêutico de um agonista trl e terapia de combinação | |
| BR112015006623A2 (pt) | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
| MX392752B (es) | Terapia de combinacion para tratar cancer. | |
| BR122019016628B8 (pt) | uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular | |
| MX2017015938A (es) | Inhibidores de ezh2 para el tratar linfomas. | |
| BR112015006093A2 (pt) | combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington | |
| BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
| BR112014018429A8 (pt) | Método para tratar um paciente que sofre de não-24, e, método para o tratamento crônico de não-24 em uma pessoa que está totalmente cega | |
| BR112017028132A2 (pt) | métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| BR112013011480A2 (pt) | método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| BR112014014783A2 (pt) | moléculas de inibidor de jnk para tratamento de várias doenças | |
| BR112013010556A2 (pt) | métodos e composições adequadas para a promoção de uma pele saudável | |
| BR112016020381A8 (pt) | sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina. | |
| BR112015017775A2 (pt) | enzima cistationina beta-sintase para o tratamento de homocistinúria | |
| BR112013007423A2 (pt) | terapia combinada no que diz respeito ao tratamento da infecção por hcv | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
| BR112015003836A2 (pt) | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 39/395 (2006.01), A61K 47/00 (2006.01), C07K |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |